Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study-Reference-Cited by-同舟云学术

Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study

Published:2018-03-26 Issue:4 Volume:35 Page:482-493
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Goldschmidt Deborah,Dalal Anand A.,Romdhani Hela,Kelkar Sneha,Guerin Annie,Gauthier Genevieve,Wu Eric Q.,Niravath Polly,Small Tania

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s12325-018-0676-2/fulltext.html

Reference16 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

2. Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. SpringerPlus. 2014;3:535.

3. American Cancer Society. Cancer facts & figures 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html .

4. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology (NCCN guidelines). Breast cancer. Version 1.2017: Fort Washington, PA. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp .

5. Shah AN, Cristofanilli M. The Growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options Oncol. 2017;18(1):6.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

2. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review;Targeted Oncology;2023-04-19

3. Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-02-28

4. Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations;JCO Precision Oncology;2022-11

5. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT;Geburtshilfe und Frauenheilkunde;2022-07-12